Correlation Engine 2.0
Clear Search sequence regions


  • children (1)
  • diarrhea (2)
  • men (2)
  • product (3)
  • shigella (4)
  • shigellosis (3)
  • spp (1)
  • Sizes of these terms reflect their relevance to your search.

    Enteric infection with Shigella spp. can lead to symptoms ranging from acute watery diarrhea to sudden, severe dysentery. Approximately 212 000 diarrheal deaths annually are attributed to Shigella with a disproportionate impact in low-resource countries. The impact in under-resourced countries was illustrated by a reanalysis of the Global Enteric Multicenter Study which found that Shigella was the leading pathogen associated with moderate-to severe diarrhea in children under 5 years old. While recent studies have highlighted the burden of the disease, there has been a concurrent reduction in therapeutic options for the treatment of shigellosis as drug resistant strains increase in prevalence. In addition, increasing reports of drug resistant shigellosis cases in the men who have sex with men community confirm that the impact is not limited to low-resource countries. Despite the urgent need for new treatments, a target product profile (TPP) has not been established, and there is no clear development path for antibacterial treatments. To address this troubling concern, this manuscript describes a TPP for antishigellosis small molecule therapeutics and a development path that integrates currently available preclinical and clinical models of Shigella infection.

    Citation

    Samuel L M Arnold. Target Product Profile and Development Path for Shigellosis Treatment with Antibacterials. ACS infectious diseases. 2021 May 14;7(5):948-958


    PMID: 33689318

    View Full Text